Nxera Pharma Co (FRA:JSS) Cyclically Adjusted PS Ratio: (As of Aug. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:JSS Nxera Pharma Co Ltd FRA:JSS
74 GF Score
Price €5.85
GF Value €4.52
! 9 Warning Signs
View Full Analysis

What is Nxera Pharma Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nxera Pharma Co  (FRA:JSS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Nxera Pharma Co Cyclically Adjusted PS Ratio Related Terms


Nxera Pharma Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Nxera Pharma Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nxera Pharma Co Cyclically Adjusted PS Ratio Chart

Nxera Pharma Co Annual Data
Trend Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.40 15.82 9.50 5.66 4.09

Nxera Pharma Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.58 4.92 4.09 4.18 0.00

FRA:JSS vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Nxera Pharma Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nxera Pharma Co Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Cyclically Adjusted PS Ratio falls into.


FRA:JSS
74GF Score
Nxera Pharma Co Ltd FRA:JSS
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nxera Pharma Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Nxera Pharma Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Nxera Pharma Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/113.6000*113.6000
=0.000

Current CPI (Jun. 2026) = 113.6000.

Nxera Pharma Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.098 98.000 0.114
201612 0.147 98.400 0.170
201703 0.228 98.100 0.264
201706 0.329 98.500 0.379
201709 0.282 98.800 0.324
201712 0.106 99.400 0.121
201803 0.065 99.200 0.074
201806 0.085 99.200 0.097
201809 0.097 99.900 0.110
201812 0.110 99.700 0.125
201903 0.326 99.700 0.371
201906 0.206 99.800 0.234
201909 0.294 100.100 0.334
201912 0.207 100.500 0.234
202003 0.121 100.300 0.137
202006 0.145 99.900 0.165
202009 0.189 99.900 0.215
202012 0.464 99.300 0.531
202103 0.116 99.900 0.132
202106 0.178 99.500 0.203
202109 0.044 100.100 0.050
202112 1.260 100.100 1.430
202203 0.105 101.100 0.118
202206 0.116 101.800 0.129
202209 0.527 103.100 0.581
202212 0.569 104.100 0.621
202303 0.080 104.400 0.087
202306 0.096 105.200 0.104
202309 0.256 106.200 0.274
202312 0.555 106.800 0.590
202403 0.317 107.200 0.336
202406 0.532 108.200 0.559
202409 0.651 108.900 0.679
202412 0.474 110.700 0.486
202503 0.458 111.100 0.468
202506 0.563 111.700 0.573
202509 0.431 112.000 0.437
202512 0.471 113.000 0.474
202603 0.403 112.700 0.406
202606 0.000 113.600 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Nxera Pharma Co (FRA:JSS) Overvalued in 2026?

Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be overvalued. The current stock price of €5.85 is trading 29.4% above its estimated GF Value™ of €4.52.

Key valuation signals for FRA:JSS:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €4.52 vs. price of €5.85 (29.4% above fair value)
  • GF Score™: 74/100 with 9 warning signs

No single metric tells the full story. See the FRA:JSS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nxera Pharma Co Business Description

Other Exchanges SOLTF:USA4565:Japan
Address Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
74GF Score

Get the complete analysis for FRA:JSS

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.85
Price
€4.52
GF Value